CurrentAmeriHealth CaritasPolicy CCP.1519

Balloon dilation of the Eustachian tube

Customize your policy alerts

Sign up for AmeriHealth Caritas Policy CCP.1519 alerts

Get alerted when Policy CCP.1519 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines coverage criteria, limitations, and required diagnostics for transnasal balloon dilation of the Eustachian tube for AmeriHealth Caritas members; applies to clinical coverage determinations for providers performing the procedure.

Policy Summary

PayerAmeriHealth Caritas

PolicyBalloon dilation of the Eustachian tube

Policy CodePolicy CCP.1519

Change TypeEvidence updateFDA clearance noted

Effective DateSep 1, 2022

Last ReviewAug 1, 2025

Next Review DateDec 1, 202639d

Key ActionObtain prior authorization confirming FDA‑cleared device, age ≥18, symptom duration ≥3 months, required objective testing, and documentation of significant impact on quality of life.

SourceLink

POLICY UPDATE CHANGES

Background and findings sections were condensed and three new systematic reviews/meta-analyses were identified and added to the evidence base.

Noted FDA expansion of clearance for the Acclarent AERA system to include pediatric patients aged 8 to 17 years.

>=3mmin symptom duration

>=18min member age

No repeatlimitation

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAmeriHealth CaritasPolicy CCP.1519

Balloon dilation of the Eustachian tube

Customize your policy alerts

Sign up for AmeriHealth Caritas Policy CCP.1519 alerts

Get alerted when Policy CCP.1519 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAmeriHealth Caritas

PolicyBalloon dilation of the Eustachian tube

Policy CodePolicy CCP.1519

Change TypeEvidence updateFDA clearance noted

Effective DateSep 1, 2022

Last ReviewAug 1, 2025

Next Review DateDec 1, 202639d

Key ActionObtain prior authorization confirming FDA‑cleared device, age ≥18, symptom duration ≥3 months, required objective testing, and documentation of significant impact on quality of life.

SourceLink

POLICY UPDATE CHANGES

Background and findings sections were condensed and three new systematic reviews/meta-analyses were identified and added to the evidence base.

Noted FDA expansion of clearance for the Acclarent AERA system to include pediatric patients aged 8 to 17 years.

>=3mmin symptom duration

>=18min member age

No repeatlimitation

Sinus/myringotomyconcurrent allowed

Coverage Criteria for Eustachian Tube Balloon Dilation

Initial therapy coverage criteria

Covered when ALL of the following are met

Primary coverage criteria: 1) Only a U.S. Food and Drug Administration device approved for balloon dilation of the Eustachian tube is used; 2) Member is 18 years or older; 3) Diagnosis of obstructive Eustachian tube dysfunction in one or both ears lasting for three months or longer; 4) Either obstructive dysfunction in isolation OR obstructive dysfunction after failed medical therapy if a treatable cause has been identified (e.g., allergic rhinitis, rhinosinusitis, laryngopharyngeal reflux); 5) Pre-procedure objective testing: otoscopy, nasal endoscopy, comprehensive audiometry, and tympanometry; 6) Diagnosis has a significant effect on quality of life or functional health status; 7) No contraindication to the procedure.

Concurrent procedure criteria

Concurrent procedures covered when criteria for each are met

Concurrent procedures allowed: Concurrent balloon dilation with sinus ostial dilation OR concurrent balloon dilation with myringotomy with or without tympanostomy tube placement is medically necessary when diagnostic criteria for each procedure are met (performed for treatment of middle ear effusion).

All other uses of balloon dilation of the Eustachian tube are considered investigational/not medically necessary. Examples specifically listed in the policy include: repeat procedure, concurrent procedure with tympanoplasty, use of a trans-tympanic approach, and procedures performed in members younger than 18 years of age.

Procedures and approaches considered investigational or not clinically proven — and therefore not medically necessary — include repeat dilation, the trans-tympanic approach, and performing balloon dilation concurrent with tympanoplasty. The policy also states that use of the procedure in members under 18 years of age is not medically necessary.

Coding and Claims Information

Covered CPT Codesmixed

No codes listed

inv-06: Symptom duration — >= 3 months

Required minimum symptom duration>= 3 months

Context from guidelinesCoverage applies when obstructive Eustachian tube dysfunction has lasted three months or longer

Relation to prior therapyPersistent symptoms ≥3 months may follow failed medical therapy when a treatable cause has been identified

inv-07: Member age — >= 18 years

Minimum member age for coverage>= 18 years

Policy notePolicy requires member be 18 years or older for transnasal balloon dilation

Provider Requirements and Authorization

Prior Authorization

Prior authorization: confirm all coverage criteria

Prior authorization must verify that all coverage criteria are met before approval: use of a U.S. Food and Drug Administration–cleared device for balloon dilation of the Eustachian tube; member age 18 years or older; diagnosis of obstructive Eustachian tube dysfunction lasting three months or longer; required pre-procedure objective testing (otoscopy, nasal endoscopy, comprehensive audiometry, and tympanometry); demonstrable significant effect on quality of life or functional status; and absence of contraindications.

Confirm device is FDA‑cleared for Eustachian tube balloon dilation.
Confirm member is ≥18 years of age.
Confirm symptoms persist ≥3 months.
Confirm required objective testing completed: otoscopy, nasal endoscopy, audiometry, tympanometry.
Document significant impact on quality of life or functional health status.
Confirm no listed contraindications are present.

Step Therapy

Background

The Eustachian tube ventilates the middle ear and connects the middle ear with the nasopharynx; obstructive Eustachian tube dysfunction can produce aural fullness, fluctuating hearing, tinnitus, pain, or imbalance and may progress to otitis media or tympanic membrane pathology. Balloon dilation transiently widens the cartilaginous lumen using an inflated catheter without mucosal resection; several FDA‑cleared devices exist and evidence demonstrates short‑term symptomatic and tympanometric improvement, with uncertainty about durability beyond three months.

Definitions and Measurement Tools

inv-13: Obstructive Eustachian tube dysfunction — definition/key features

DefinitionObstructive Eustachian tube dysfunction: impairment of Eustachian tube ventilation causing aural fullness, fluctuating hearing, tinnitus, ear pain, or imbalance and can lead to chronic otitis media or tympanic-membrane retraction

Diagnostic confirmationRequires complete history plus objective testing: nasal endoscopy, otoscopy, tympanometry, comprehensive audiometry, and assessment of pressure-equalizing maneuver

When procedure consideredBalloon dilation is considered when dysfunction persists despite conservative therapy or when it significantly affects quality of life

inv-14: Validated symptom score referenced for objective symptom quantification — Seven-item Eustachian Tube Dysfunction Questionnaire

Validated instrumentSeven-item Eustachian Tube Dysfunction Questionnaire (ETDQ-7)

Policy Summary

PayerAmeriHealth Caritas

PolicyBalloon dilation of the Eustachian tube

Policy CodePolicy CCP.1519

Change TypeEvidence updateFDA clearance noted

Effective DateSep 1, 2022

Last ReviewAug 1, 2025

Next Review DateDec 1, 202639d

Key ActionObtain prior authorization confirming FDA‑cleared device, age ≥18, symptom duration ≥3 months, required objective testing, and documentation of significant impact on quality of life.

SourceLink

On This Page

Contrast with FDA clearance

FDA clearance expansion to ages 8–17 is noted in background but policy retains ≥18 requirement

Conservative therapy expectations before dilation

Prior to requesting dilation, document that conservative measures were attempted or considered: appropriate medical therapy for underlying etiologies (for example, allergic rhinitis, rhinosinusitis, laryngopharyngeal reflux) and alternative covered surgical options such as adenoidectomy, myringostomy, or tympanostomy tube insertion when indicated.

Record trials of medical therapy for identifiable treatable causes and response.
Consider and document alternative covered services (adenoidectomy, myringostomy, tympanostomy tube insertion) when appropriate.

Documentation Required

Required documentation to support medical necessity

Include documentation that supports each coverage element: device used is FDA‑cleared, member age ≥18 years, diagnosis of obstructive Eustachian tube dysfunction lasting ≥3 months, results of required pre‑procedure objective testing, prior medical therapy details if applicable, and evidence of significant impact on quality of life.

Specify the FDA‑cleared device used for the procedure.
Document member date of birth or age confirming ≥18 years.
Provide history showing symptoms ≥3 months and diagnosis.
Attach results of otoscopy, nasal endoscopy, comprehensive audiometry, and tympanometry.
Detail prior medical treatments and response when dilation is after failed therapy.
Include notes or instruments demonstrating significant impact on quality of life (e.g., validated symptom score).

Denial Risk

Common triggers for denial

Requests may be denied if the procedure is a repeat dilation, performed via a trans‑tympanic approach, done concurrently with tympanoplasty, or requested for members younger than 18 years, because these uses are considered investigational/not medically necessary.

Do not request repeat balloon dilation without clear justification; repeat procedures are considered investigational.
Avoid trans‑tympanic approach requests; this approach is listed as investigational.
Do not submit requests for members <18 years; policy requires age ≥18.
Do not request concurrent tympanoplasty with dilation; this combination is investigational.

Referenced for objective symptom quantification alongside otoscopy, nasal endoscopy, tympanometry, and audiometry

Guideline supportConsensus statement recommends use of the seven-item questionnaire to quantify symptom burden